The juvenile toxicity study as a tool for a science-based risk assessment in the children population group

Laura Narciso1, Tiziana Catone2, Gabriele Aquilina2

  • 1Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Rome, Italy.

Insights

Children face unique chemical risks due to developmental factors. This study proposes updated juvenile toxicity testing to better characterize these risks for regulatory safety assessments.

Area of Science:

  • Environmental Health
  • Toxicology
  • Developmental Biology

Background:

  • Children possess distinct vulnerabilities to chemical hazards because of developmental changes and varied exposure routes.
  • Regulatory frameworks mandate children's risk characterization, yet current testing guidelines often overlook post-natal development, except for pesticides and biocides.
  • Existing toxicological tests for pediatric drugs are insufficient for evaluating direct exposure effects on immature organisms.

Purpose of the Study:

  • To discuss a testing strategy for identifying and characterizing chemical hazards from a child-specific viewpoint.
  • To address regulatory needs for robust children's risk assessment.
  • To propose an update to existing guidelines for incorporating juvenile toxicity endpoints.

Main Methods:

  • Review of current regulatory testing guidelines and their limitations regarding juvenile toxicity.
  • Discussion of criteria for selecting chemicals requiring juvenile toxicity testing.
  • Proposal for updating existing test protocols with specific triggers for juvenile-relevant endpoints.

Main Results:

  • Current testing guidelines are inadequate for comprehensive children's chemical risk assessment.
  • Juvenile toxicity testing is crucial for chemicals with specific modes of action, age-related toxicokinetics, or significant child exposure.
  • Updating existing guidelines with juvenile-specific endpoints is a viable approach.

Conclusions:

  • A child-specific testing approach is necessary to meet regulatory requirements for chemical hazard characterization.
  • Implementing juvenile toxicity testing, guided by specific triggers, will enhance the protection of children from chemical risks.
  • Updating existing toxicological guidelines is key to ensuring the safety of chemicals for developing populations.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
63
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
59
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
81